Provided by Tiger Trade Technology Pte. Ltd.

BOAN BIOTECH

2.625
+0.0953.75%
Volume:1.25M
Turnover:3.20M
Market Cap:1.61B
PE:180.95
High:2.715
Open:2.715
Low:2.420
Close:2.530
52wk High:15.140
52wk Low:2.420
Shares:614.00M
HK Float Shares:614.00M
Volume Ratio:0.26
T/O Rate:0.20%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.015
ROE:-4.11%
ROA:-1.28%
PB:0.52
PE(LYR):180.95
PS:2.21

Loading ...

Boan Biotech Buys Back 2.00 Million H Shares, Spending HKD 7.47 Million

Bulletin Express
·
Aug 28

Shandong Boan Biotech Files HKEX Next-Day Return Disclosing Share Buyback at HKD 3.74 Each

Reuters
·
Aug 28

Boan Biotech Posts RMB 83.00 Million Interim Loss as Revenue Falls 40.8% on Procurement Pressure

Bulletin Express
·
Aug 27

BOAN BIOTECH Signs Finance Lease Agreement

Stock News
·
Aug 27

BOAN BIOTECH Posts First-Half Loss as Revenue Slips on Policy Expectations

Stock News
·
Aug 27

Shandong Boan Biotechnology- Leased Assets Refer to Certain Machinery & Equipment Leased by Industrial Bank Financial Leasing

THOMSON REUTERS
·
Aug 27

Shandong Boan Biotechnology Co - Purchase Price for Leased Assets is Rmb75.00 Mln

THOMSON REUTERS
·
Aug 27

Shandong Boan Biotechnology Co Ltd - Industrial Bank Financial Leasing Will Purchase Leased Assets from Co

THOMSON REUTERS
·
Aug 27

Shandong Boan Biotech Enters RMB 75 Million Sale-and-Leaseback Deal with Industrial Bank Financial Leasing

Reuters
·
Aug 27

Shandong Boan Biotech Swings to FY26 H1 Net Loss of RMB 83.01 Million; Revenue Drops 40.8% to RMB 233 Million

Reuters
·
Aug 27

Boan Biotech Secures CDE IND Nod for First-in-Class TL1A/IL-23 Bispecific Antibody BA2201 to Treat IBD

Bulletin Express
·
Aug 26

BOAN BIOTECH (06955) Submits IND for BA2201 (TL1A/IL-23) as CDE Accepts Clinical Trial Application

Stock News
·
Aug 26

Shandong Boan Biotech Says China CDE Accepts IND Filing for Ba2201 Bispecific Antibody

Reuters
·
Aug 26

Shandong Boan Biotechnology Co Ltd - Cde Acceptance of Ind Application for Tl1a/Il-23 Bispecific Antibody Ba2201

THOMSON REUTERS
·
Aug 26

Bioan Biotech's BA1302 (CD228 ADC) Completes China Phase Ia Clinical Study

Stock News
·
Aug 14

BOAN Biotech Schedules 27 Aug 2026 Board Meeting to Approve 1H26 Results and Assess Interim Dividend

Bulletin Express
·
Aug 14

BOAN BIOTECH (06955) Warns of Loss, Expects Net Loss Attributable to Shareholders of Approximately RMB 79 Million to RMB 89 Million for the First Half of the Year, a Swing from Profit to Loss

Stock News
·
Aug 14

Shandong Boan Biotechnology Expects Net Loss Attributable of RMB79 Million-RMB89 Million

Reuters
·
Aug 14

Shandong Boan Biotech Completes China Phase Ia Trial of Ba1302 CD228-Targeted ADC

Reuters
·
Aug 14

Shandong Boan Biotechnology Co - Expected Turnaround to Loss Mainly Due to Increased R&D Expenditure in Hy

THOMSON REUTERS
·
Aug 14